COMMUNIQUÉS West-GlobeNewswire

OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
15/03/2018
Acuitas® AMR Gene Panel u5.47 introduced for Research Use Only Fourth quarter revenue consistent with previous year; net loss decreases 38% year over year Conference call begins at 4:30 p.m. Eastern time today [...]
Ovid Therapeutics to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Thursday, March 29, 2018
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID ), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that its [...]
GBT Announces New Employment Inducement Grants
15/03/2018
SOUTH SAN FRANCISCO, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced that on March 12, 2018, the compensation committee of the Company’s board of directors [...]
Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
15/03/2018
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT ), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and [...]
Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
15/03/2018
STAMFORD, Conn., March 15, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and [...]
CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update
15/03/2018
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies [...]
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
15/03/2018
Conference Call & Live Webcast Today at 4:30pm Eastern Time LIVONIA, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP ), a clinical-stage biopharmaceutical company focused on [...]
Rockwell Medical Reports Fourth Quarter and Year End 2017 Results
15/03/2018
Conference call at 4:30 p.m. EDT today WIXOM, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI ), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and [...]
Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2018
15/03/2018
WEST LAFAYETTE, Ind., March 15, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT ), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that four posters [...]
Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania
15/03/2018
YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN ), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinose was [...]
Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2017 Financial Results, Business Progress Against Plan and Recent Accomplishments
15/03/2018
Revenue for the Quarter Grew 40% over the Comparable Prior Year Quarter and 21% for the Full Year, Raising $30 Million in Equity and Significantly Improving Balance Sheet and Cash Position, Reimbursement Continued to [...]
BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
15/03/2018
Full-year 2017 net revenue of $62.0 million vs. $15.5 million in 2016 BELBUCA ® fourth quarter 2017 net revenue of $9.4 million vs. $6.4 million in third quarter; an increase of 47% BELBUCA prescription growth of 84% in [...]
Tokyo Smoke launches innovative educational events and resources
15/03/2018
TORONTO, March 15, 2018 (GLOBE NEWSWIRE) -- Tokyo Smoke , a subsidiary of Hiku Brands (“Hiku”) (CSE:HIKU), Canada’s first vertically-integrated cannabis brand house, is excited to announce ‘ Higher Learning ’, a brand- [...]
Bradmer Pharmaceuticals, Galaxy Digital and First Coin Announce Update
15/03/2018
TORONTO, March 15, 2018 (GLOBE NEWSWIRE) -- NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES. Bradmer Pharmaceuticals Inc. (“ Bradmer ”) (TSX VENTURE:BMR.H), Galaxy Digital LP (“ [...]
Akers Biosciences Announces Conference Call to Discuss Fiscal Year 2017 Earnings
15/03/2018
THOROFARE, N.J, March 15, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, will hold a conference call [...]
OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
15/03/2018
Phase 3 Trial received Approval to be Initiated in Israel Patient Accrual Already Resumed in the U.S. NANTES, France, March 15, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE), today [...]
ThromboGenics Business Update - FY 2017
15/03/2018
Press release 15 March 2018 Regulated Information Advancing Preclinical and Clinical Diabetic Eye Disease Portfolio Regained global rights to JETREA ® from Alcon, a Novartis company, and received €53.7 million in cash [...]
Elsalys Biotech : LEUKOTAC at the 44th congress of the European Society for Blood and Marrow Transplantation (EBMT)
15/03/2018
LEUKOTAC ® at the 44 th congress of the European Society for Blood and Marrow Transplantation (EBMT) A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid- [...]
Elsalys Biotech : LEUKOTAC® au 44ème congrès européen de greffe de moelle (EBMT)
15/03/2018
LEUKOTAC ® au 44 ème congrès européen de greffe de moelle (EBMT) Un poster résumant les résultats sur le profil de sécurité de la Phase 3 randomisée testant LEUKOTAC® chez les patients atteints d'une forme aigüe et [...]

Pages